Rituximab as a sole steroid-sparing agent in generalized myasthenia gravis: Long-term outcomes

Kefalopoulou, Zinovia-Maria; Veltsista, Dimitra; Germeni, Alexandra; Lykouras, Dimosthenis; Tsiamaki, Eirini; Chroni, Elisabeth

doi:10.1007/s10072-023-07082-3

Neurol Sci

2023

DOI: 10.1007/s10072-023-07082-3

|View full text |Cite

Rituximab as a sole steroid-sparing agent in generalized myasthenia gravis: Long-term outcomes

Zinovia-Maria Kefalopoulou,

Dimitra Veltsista,

Alexandra Germeni

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Eculizumab Versus Rituximab for Refractory Antiacetylcholine Receptor Antibody‐Positive Generalized Myasthenia Gravis: A Single‐Center Experience

Durmus,

Çakar,

Parman

2024

Acta Neurologica Scandinavica

View full text Add to dashboard Cite

Background: Rituximab (RTX) and eculizumab (ECU) are treatment options for refractory myasthenia gravis (MG), but comparative clinical data derived from real‐world experience are limited. Here, we describe the baseline characteristics, treatment, and safety outcomes of patients with antiacetylcholine receptor antibody‐positive (AChR+) generalized myasthenia gravis (gMG) treated with ECU and/or RTX in our clinic.Methods: Patients with refractory AChR+ gMG who received ECU or/and RTX treatment for more than 1 year at the Department of Neurology, Istanbul Faculty of Medicine were included in this observational study. After obtaining written patient consent, data were collected retrospectively from medical records.Results: Twelve patients treated with ECU and 25 patients treated with RTX were included in the analysis. Groups were comparable with regard to demographic and clinical characteristics, including age at onset of MG, disease duration, and history of thymoma. ECU was associated with significantly better outcomes compared with RTX, as measured by decreases in the mean MG activities of daily living score at 1 (p = 0.024), 3 (p < 0.001), 6 (p < 0.001), and 12 (p < 0.001) months of treatment; steroid‐sparing effect after 1 year of treatment (decrease in mean [standard deviation] daily prednisolone dose of −21.8 mg [13.5] vs. −6.6 mg [9.4] with RTX; p < 0.001); and need for rescue treatment and number of myasthenic crisis episodes during treatment (p < 0.001). No new safety signals were observed with either treatment.Conclusion: Our data provide real‐world evidence supporting ECU over RTX to treat patients with refractory AChR+ gMG.

show abstract

Eculizumab Versus Rituximab for Refractory Antiacetylcholine Receptor Antibody‐Positive Generalized Myasthenia Gravis: A Single‐Center Experience

Durmus,

Çakar,

Parman

2024

Acta Neurologica Scandinavica

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Rituximab as a sole steroid-sparing agent in generalized myasthenia gravis: Long-term outcomes

Cited by 1 publication

References 38 publications

Eculizumab Versus Rituximab for Refractory Antiacetylcholine Receptor Antibody‐Positive Generalized Myasthenia Gravis: A Single‐Center Experience

Eculizumab Versus Rituximab for Refractory Antiacetylcholine Receptor Antibody‐Positive Generalized Myasthenia Gravis: A Single‐Center Experience

Contact Info

Product

Resources

About